A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN).
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Merck KGaA
- 09 Nov 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Mar 2011 New trial record